磷酸二酯酶5抑制剂治疗与间质性肺疾病相关肺动脉高压患者生存的贝叶斯回顾性队列研究
本研究纳入128例经右心导管确诊的间质性肺疾病相关肺动脉高压(ILD-PH)患者,采用贝叶斯方法分析磷酸二酯酶5抑制剂(PDE5i)治疗与生存的关系。结果显示,接受PDE5i治疗的患者中位生存期显著长于未治疗者(2.18年 vs 0.94年,p=0.003),且该获益独立于其他预后因素。
要点
- PDE5i治疗与ILD-PH患者生存改善独立相关(HR 0.39)。
- 右心室功能正常者接受PDE5i治疗的生存获益更显著。
- 需前瞻性随机试验进一步验证PDE5i在ILD-PH中的疗效。
核心结论
- PDE5i治疗与ILD-PH患者生存改善独立相关,但需前瞻性随机试验验证。
研究设计与样本
- 回顾性观察性队列研究,纳入128例连续新发ILD-PH患者,均接受右心导管、超声心动图和肺功能检查,采用贝叶斯方法建模分析。
主要发现
- PDE5i治疗组(n=50,39%)中位生存期2.18年(95% CI:1.43,3.04),未治疗组0.94年(95% CI:0.69,1.51),p=0.003。
- 贝叶斯联合模型显示PDE5i治疗与生存独立相关(HR 0.39,95% CI:0.23,0.59,p<0.001)。
- 倾向性匹配分析同样显示PDE5i治疗与生存改善相关(HR 0.38,95% CI:0.22,0.58,p<0.001)。
- 右心室功能正常者接受PDE5i治疗的生存差异更大(+2.55年,95% CI:-0.03,+3.97),而右心室功能异常者为+0.98年(95% CI:+0.47,+2.00),p=0.04。
临床怎么用
- 在ILD-PH患者中,PDE5i治疗可能与生存改善相关,尤其右心室功能正常者可能获益更多。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Pulmonary hypertension is a life-limiting complication of interstitial lung disease (ILD-PH). We investigated whether treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with ILD-PH was associated with improved survival. METHODS: Consecutive incident patients with ILD-PH and right heart catheterisation, echocardiography and spirometry data were followed from diagnosis to death, transplantation or censoring with all follow-up and survival data modelled by Bayesian methods. RESULTS: The diagnoses in 128 patients were idiopathic pulmonary fibrosis (n = 74, 58%), hypersensitivity pneumonitis (n = 17, 13%), non-specific interstitial pneumonia (n = 12, 9%), undifferentiated ILD (n = 8, 6%) and other lung diseases (n = 17, 13%). Final outcomes were death (n = 106, 83%), transplantation (n = 9, 7%) and censoring (n = 13, 10%). Patients treated with PDE5i (n = 50, 39%) had higher mean pulmonary artery pressure (median 38 mm Hg [interquartile range, IQR: 34, 43] vs. 35 mm Hg [IQR: 31, 38], p = 0.07) and percentage predicted forced vital capacity (FVC; median 57% [IQR: 51, 73] vs. 52% [IQR: 45, 66], p=0.08) though differences did not reach significance. Patients treated with PDE5i survived longer than untreated patients (median 2.18 years [95% CI: 1.43, 3.04] vs. 0.94 years [0.69, 1.51], p = 0.003) independent of all other prognostic markers by Bayesian joint-modelling (HR 0.39, 95% CI: 0.23, 0.59, p < 0.001) and propensity-matched analyses (HR 0.38, 95% CI: 0.22, 0.58, p < 0.001). Survival difference with treatment was significantly larger if right ventricular function was normal, rather than abnormal, at presentation (+2.55 years, 95% CI: -0.03, +3.97 vs. +0.98 years, 95% CI: +0.47, +2.00, p = 0.04). CONCLUSION: PDE5i treatment in ILD-PH should be investigated by a prospective randomized trial.
引用
- Dawes TJW, McCabe C, Dimopoulos K, et al. Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. Respirology. 2022. PMID: 36172951. doi:10.1111/resp.14378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。